Immuno-Oncology: Taking Immunotherapies to the Next Level (BIO 2019)
- Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting, formerly Defined Health
- Jennifer Buell, Chief Operating Officer, Agenus, Inc.
- Asthika Goonewardene, Senior Biotechnology Analyst, Bloomberg Intelligence
- Bibhash Mukhopadhyay, Principal, New Enterprise Associate
- Drew Pardoll, Abeloff, Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
- Helen Sabzevari, President, Precigen
- Emmett Schmidt, Associate Vice President at Merck & Co., Inc., North Wales Pennsylvania UNITED STATES
We have seen great strides in the approval of cancer immunotherapies, treatments that harness the powers of the immune system to battle cancer. Although recent breakthroughs in cancer immunotherapy have deepened our understanding of the mechanisms and pathways that regulate the immune’s system response to cancer, the leading agents, the checkpoint inhibitors (CPIs), while demonstrating dramatic effects in certain cancers and patients, in other settings have shown only modest if not negligible clinical benefit. Hence there remains a high unmet need for additional therapies, in particular to be used in combination with CPIs to enhance activity, especially to reverse innate or acquired resistance. This panel will discuss the future of immuno-oncology and combination strategies, new generation of checkpoint inhibitors and novel mechanisms of action for immune engagement.